Market Cap (In USD)
1.55 Million
Revenue (In USD)
785 Thousand
Net Income (In USD)
-39.47 Million
Avg. Volume
62.26 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.5266-13.14
- PE
- -0.045
- EPS
- -11.69
- Beta Value
- 1.358
- ISIN
- US68236P2065
- CUSIP
- 68236P107
- CIK
- 1260990
- Shares
- 2959640.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. James B. Breitmeyer M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.oncternal.com
- Ipo Date
- 2004-02-03
- Details
- Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
More Stocks
-
600596
-
DRL
-
2876Delsole Corporation
2876
-
688425
-
OGI
-
PNGAY
-
NBNNortheast Bank
NBN
-
SF-PCStifel Financial Corp.
SF-PC